Press Releases MaaT Pharma

Equities

MAAT

FR0012634822

Real-time Euronext Paris Other stock markets 08:00:13 10/05/2024 BST			5-day change	1st Jan Change
9.44 ^EUR	-0.21%		+0.43%	+35.24%

05-08	Mickey Mouse on Wall Street
04-15	MaaT Pharma: positive data in graft-versus-host disease	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024	05-07	BU
MaaT Pharma to Hold Annual General Meeting on May 28, 2024	04-22	BU
Long-term data indicates "significant" potential of aGvHD microbiome treatment	04-15	AQ
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	04-15	BU
Advancing microbiome innovation	04-10	AQ
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies	04-08	BU
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont, Groupe Societe Generale	04-08	AQ
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale	04-05	BU
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview	03-28	BU
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer	03-21	BU
MaaT Pharma to Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients Responses to Immunotherapies	03-20	AQ
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies	03-19	BU
MaaT Pharma : Inside Information / Other news releases	03-12	PU
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference	03-12	BU
MaaT Pharma Releases its 2024 Financial Calendar	03-07	BU
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma	03-06	AQ
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis	03-01	AQ
MaaT Pharma, Half-year Report on Liquidity Contract with the Brokerage Firm Kepler Cheuvreux	01-23	AQ
MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023	12-12	AQ
ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease	12-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MaaT Pharma

Equities

MAAT

FR0012634822

Press Releases

Filters